Drug Trial Radar · NCT05394103
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Aug 30, 2022
Primary completion
Mar 31, 2029
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- Qurient Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- May 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Conditions
- Advanced Cancer
- Metastatic Cancer
Interventions
Mocaciclib (Q901)Drug
The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
KEYTRUDA® (pembrolizumab)Drug
KEYTRUDA® (pembrolizumab) will be administered Q6W
FulvestrantDrug
Fulvestrant will be administered as per the drug label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: 28 days of cycle 1 (each cycle is 28 days)
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona · Recruiting
University of Southern California
Los Angeles, California · Recruiting
Mayo Clinic
Jacksonville, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Atlantic Health System Hospital
Morristown, New Jersey · Recruiting
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
Keimyung University
Daegu, South Korea · Recruiting
National Cancer Center
Goyang-si, South Korea · Recruiting
CHA University Bundang Medical Center
Seongnam-si, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Seoul National University
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Ajou University
Suwon, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.